Mustafa Khasraw, MD, discusses the purpose II VERTU study and shares key takeaways from his presentation at the 2019 Society for NeuroOncology Annual Meeting.
Mustafa Khasraw, MD, deputy directoy, medical oncologist and nuerologist, Duke Center for Cancer Immunotherapy, Duke Cancer Center, Duke Health, discusses the purpose of the phase II VERTU study and shares key takeaways from his presentation at the 2019 Society for NeuroOncology Annual Meeting
The study randomized patients to standard treatment (radiotherapy) plus temzolomide chemotherapy for glioblastoma or the combination of PARP inhibitor veliparib (ABT-888) with radiotherapy followed by temzolomide in combination with veliparib, which was the experimental arm of the trail. The study included patients with glioblastoma who have a poor prognosis due to an unmethylated enzyme called MGMT. The purpose of the experiment was to make DNA-repair inefficient so that cancer cells would be eliminated.
The experimental combination did not improve survival in patients with unmethylated MGMT glioblastoma despite previous signals of activity in animal subjects, which was the rationale for the VERTU study.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More